The real revolution came in 2012, when researchers Jennifer Doudna and Emmanuelle Charpentier harnessed CRISPR, a natural bacterial defense system. In bacteria, CRISPR cuts out invading viruses’ DNA ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

Earlier this year, researchers at Children's Hospital of Philadelphia and Penn created a first-of-its-kind drug customized to a unique genetic mutation to save an infant named Baby KJ from dying of a ...

The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...

A study of mosquitoes’ circadian rhythms finds they hunt differently at different times of day. It could help stop their ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

Sohini Ramachandran is a professor of biology, data science, and computer science at Brown University. C. Brandon Ogbunu is ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

Oscar-winning filmmaker Guillermo del Toro was honored with SFFilm's Sloan Science in Cinema Prize for "Frankenstein," an ...

One person’s side effect could be another person’s treatment if we expand our perspective on small molecule drug targets, ...

GATC brought together a broad coalition of researchers and executives in cell and gene therapy, gene editing, drug discovery and AI as well as patients and advocates.

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...